Sugi Predict

Sugi Predict / Targets / SCN1B

SCN1B

Sodium channel regulatory subunit beta-1 · Q07699 · SCN1B on Sugi Atlas →

8,623 patent compounds predicted against SCN1B, 6,026 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL6840243 SCHEMBL6840243 0.70 13/20
SCHEMBL6840201 SCHEMBL6840201 0.68 11/20
SCHEMBL6840202 SCHEMBL6840202 0.53 11/20
SCHEMBL6840241 SCHEMBL6840241 0.68 10/20
SCHEMBL10324725 SCHEMBL10324725 0.53 10/20
SCHEMBL10325019 SCHEMBL10325019 0.52 10/20
SCHEMBL10380538 SCHEMBL10380538 0.51 10/20
SCHEMBL10379940 SCHEMBL10379940 0.46 10/20
SCHEMBL10379447 SCHEMBL10379447 0.46 10/20
SCHEMBL10380145 SCHEMBL10380145 0.44 10/20
SCHEMBL10380476 SCHEMBL10380476 0.43 10/20
SCHEMBL10379580 SCHEMBL10379580 0.40 10/20
SCHEMBL12089856 SCHEMBL12089856 0.52 9/20
SCHEMBL366784 SCHEMBL366784 0.50 9/20
SCHEMBL10324443 SCHEMBL10324443 0.47 9/20
SCHEMBL2632994 SCHEMBL2632994 0.59 7/20
SCHEMBL1350297 SCHEMBL1350297 0.56 7/20
SCHEMBL2626891 SCHEMBL2626891 0.59 6/20
SCHEMBL3168368 SCHEMBL3168368 0.56 6/20
SCHEMBL1350247 SCHEMBL1350247 0.53 6/20

Clinical trials — most relevant to SCN1B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations PHASE4COMPLETED
Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age PHASE4RECRUITING
Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy PHASE3COMPLETED
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome PHASE3RECRUITING
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety PHASE3RECRUITING
Comparison of Effectiveness of Ranolazine Plus Metoprolol Combination vs. FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation PHASE2/PHASE3WITHDRAWN
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome PHASE1/PHASE2COMPLETED
Verapamil as Therapy for Children and Young Adults With Dravet Syndrome PHASE2COMPLETED
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only) PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Mutation-specific Therapy for the Long QT Syndrome PHASE2COMPLETED
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome PHASE1/PHASE2RECRUITING
An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome PHASE2ACTIVE_NOT_RECRUITING
Pathophysiology Based Therapy of Early Onset Epileptic Encephalopathies PHASE2WITHDRAWN
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN) PHASE1/PHASE2RECRUITING
Sodium Channel Splicing in Heart Failure Trial nanCOMPLETED
SCN1A Horizons A Natural History Study of SCN1A-related Epilepsies in the United Kingdom nanRECRUITING
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study nanUNKNOWN
ST-segment Elevation as an AF Endophenotype nanCOMPLETED
Treatment of Gait Disorders in Children With Dravet Syndrome nanCOMPLETED
Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA) nanCOMPLETED
Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation nanRECRUITING
EXploring novEl Molecular Determinants of DRAvet Syndrome Phenotype Heterogeneity nanUNKNOWN
Factors Affecting Salt Intake in Young Adults nanUNKNOWN
A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy nanCOMPLETED
Secondary Central Nervous System Lymphoma Registry - Charité nanUNKNOWN
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients. nanUNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Genotype, Phenotype, and Disease Progression of Developmental Epileptic Encephalopathy With Onset Before 2 Years of Age nanRECRUITING
fMRI-study in Patients With Small Fiber Neuropathy nanUNKNOWN
GABA Biomarkers in Dravet Syndrome nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a SCN1B binder may also engage these)

ProteinNameSimilarity
A5A6L6 — 1.000 A5A6L6 →
Q17QN4 — 1.000 Q17QN4 →
Q4PPC4 — 1.000 Q4PPC4 →
Q00954 — 1.000 Q00954 →
P53788 — 1.000 P53788 →
P97952 — 1.000 P97952 →
Q3V3F6 — 0.966 Q3V3F6 →
Q5EAB0 — 0.965 Q5EAB0 →
Q30631 — 0.964 Q30631 →
Q6UWV2 — 0.964 Q6UWV2 →
A5D7C3 — 0.961 A5D7C3 →
O60487 — 0.959 O60487 →
P14439 — 0.959 P14439 →
O70255 — 0.959 O70255 →
P01904 — 0.958 P01904 →
A3KPA0 — 0.958 A3KPA0 →
Q5R804 — 0.957 Q5R804 →
Q2WGK2 — 0.957 Q2WGK2 →
Q68FQ2 — 0.956 Q68FQ2 →
Q6DJ83 — 0.956 Q6DJ83 →
P57087 — 0.956 P57087 →
P04224 — 0.956 P04224 →
P04228 — 0.955 P04228 →
Q63621 — 0.955 Q63621 →
Q9BX67 — 0.955 Q9BX67 →
Q9NPH3 — 0.955 Q9NPH3 →
P01903 — 0.954 P01903 →
Q61730 — 0.954 Q61730 →
Q3TEW6 — 0.954 Q3TEW6 →
Q66KX2 — 0.954 Q66KX2 →